<DOC>
	<DOCNO>NCT01014286</DOCNO>
	<brief_summary>The primary objective protocol determine frequency oncogenic mutation 1000 patient advance adenocarcinoma lung . The link clinical mutational analysis use determine frequency mutation , association clinical feature outcome , association mutation . As future therapeutic protocol specific mutation develop , patient may notify eligibility study . Future translational study may use : ) unravel complex biology lung cancer ; b ) identify prognostic marker ; c ) define predictive marker response/resistance new therapy ; ) identify new target . A secondary goal establish consortium site capability conduct multiple mutation test Clinical Laboratory Improvement Amendments ( CLIA ) certify lab .</brief_summary>
	<brief_title>Lung Cancer Mutation Consortium Protocol</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<criteria>1 . Subjects ( = &gt; 18 year age ) undergo evaluation diagnosis treatment advance adenocarcinoma lung . 2 . Diagnosed May 2012 later 3 . Oral write informed consent . 1 . Lung cancer histology adenocarcinoma 2 . Lack adequate tissue .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>